FRI0609 USEFULNESS OF FDG-PET/CT IMAGING AND SEROLOGICAL

BIOMARKERS TO PREDICT RELAPSE IN IGG4-RELATED DISEASE
M. Kato, H. Ozaki, T. Kameda, M. Izumikawa, S. Nakashima, H. Shimada, R. Wakiya, A. Kondo, N. Kadowaki, H. Dobashi. Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan Background: IgG4-RD shows relapses frequently. It is important to search to the factors to predict relapse. Recent research has shown the usefulness of FDG-PET/CT for IgG4-RD because it is more sensitive than conventional imaging to detect organ involvement of the disease. It has been suggested that FDG-PET/CT is also useful for monitoring therapeutic response of IgG4-RD. Objectives: We investigate the usefulness of FDG-PET/CT imaging and serological biomarkers to predict relapse in IgG4-RD. Methods: We analyzed 24 patients with IgG4-RD treated for more than 1 year between 2008 and 2016 in our facility. The diagnosis for IgG4-RD was based on comprehensive diagnostic criteria for IgG4-RD. All cases underwent FDG-PET/CT at least once, and laboratory data were collected from their medical records retrospectively. Levels of serum C-reactive protein (CRP), eosinophil/leukocyte ratio, serum IgG, IgG4, IgA, IgM, IgE, sIL2-R and serum compliment were investigated. Results: The patients had a mean age of 67.9 years (range: 50-87 years). In the cases with high FDG uptake on FDG-PET/CT, they had a greater number of organ involvements, higher serum IgG and sIL-2R levels. Eight patients experienced relapses following treatment. Higher serum IgG predicted relapses of IgG4-RD. FDG-PET/CT findings at baseline were not associated with relapse. FDG-PET/CT was performed in 13 patients after initiation of treatment and 4 patients had a relapse. There were no significant reduction of abnormal FDG uptake in 6 patients, and 4 of 6 patients relapsed. Conclusions: In this study, we examined the factors to predict relapse in IgG4-RD. Patients with higher serum IgG were regarded as a risk of relapse, but FDG-PET/CT findings at baseline were not associated with relapse. FDG-PET/CT reexamined after initiation of treatment is useful to predict relapse of IgG4-RD. Background: The diagnosis of FMF (Familial Mediterranean Fever) can be missed or delayed even in a country like Turkey, one of the most prevalent places for FMF (1). Objectives: We compared the duration of delay in diagnosis before and after year 2000, and assessed the problems related with the diagnosis of FMF. Methods: We studied 143 (102 F, 41 M) consecutive patients with FMF seen at the rheumatology outpatient clinic, between November 2016 and January 2017. Patients completed a self-administered questionnaire that assesses initial symptoms, previous diagnosis and treatments received before the formal diagnosis of FMF. Patients were divided in 2: as Group 1, which includes 70 patients seen for the first time by a physician before 2000 and Group 2, which includes 73 patients seen after 2000. Results: The median age of the patients was 34 years . The F/M ratio was 2.4. The initial symptom was abdominal pain in the majority (n=134, 89%), followed by fever (n=114, 75%), arthritis (n=66, 44%), pleuritic pain (n=21, 14%), arthralgia (n=11, 7%) and other complaints (n=14, 9%). The median age at initial symptom was 10 years (IQR:6-23). The median delay in diagnosis was 8 years . This was significantly shorter in Group 2 (median: 4 years [IQR:0-11]) than that observed in Group 1 (median: 10 years [IQR:6-17]), as shown in Table. A total of 110 patients (73%) were diagnosed with one or more diseases or syndromes other than FMF. These were appendicitis (n=50, 45%), gastrointestinal diseases (n=44, 40%), acute rheumatic fever (n=36, 33%), inflammatory
